Disc Medicine, Inc.
IRON Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$74.51
KIRA · Stoqly’s AI analyst, in plain words
- Disc Medicine, Inc. lost $212M in fiscal 2025.
- Free cash flow was −$181M in fiscal 2025, — of revenue.
- Disc Medicine, Inc. has $762M more cash than debt.
Market cap
$2.9B
P/E
—
Revenue
—
Net income
−$212M
Free cash flow
−$181M
Operating margin
—
Disc Medicine, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$212M
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Disc Medicine, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Disc Medicine, Inc.
- CIK
- 0001816736
Disc Medicine, Inc. · IRON
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$36.0M | −$46.8M | −$76.4M | −$109M | −$212M |
| Diluted EPS | −$40.95 | −$45.05 | −$3.42 | −$3.96 | −$6.01 |
| Cash | |||||
| Cash from operations | −$27.5M | −$42.3M | −$73.5M | −$93.9M | −$180M |
| Capital expenditure | $0.1M | $0.2M | $0.1M | $0.5M | $0.9M |
| Free cash flow | −$27.6M | −$42.4M | −$73.6M | −$94.4M | −$181M |
| Share count change | −94.2% | 18.3% | 2,046.8% | 23.7% | 27.9% |
| Debt and strength | |||||
| Cash and short-term investments | $88.0M | $195M | $360M | $490M | $791M |
| Debt incl. finance leases | — | — | $0.0M | $28.3M | $29.2M |
| Shareholders' equity | −$64.2M | $177M | $345M | $444M | $740M |
| Current ratio | 6.7x | 8.8x | 17.1x | 21.2x | 21.9x |
| Interest coverage | −14.3x | — | — | −226.8x | −65.4x |
| Returns and quality | |||||
| Return on equity | — | −83.3% | −29.3% | −27.7% | −35.9% |
| Return on tangible equity | — | −26.5% | −22.1% | −24.7% | −28.7% |
| Piotroski F-score | — | — | — | 2 | 3 |
| Altman Z'' | −3.7 | 10.2 | 18.6 | 11.3 | 13.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$50.0M
7 insiders
Of sales under plans
59%
$29.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Disc Medicine, Inc. · IRON
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $74.51 a share, the company is worth $2.9B.
Source: SEC EDGAR XBRL filings (CIK 0001816736). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.